Patients Rising Blog | Patient Stories, Policy Insights & News

Why We Wrote to the White House About Black-Market Weight-Loss Compounds

Written by Patients Rising Staff | November 18, 2026 at 11:03 PM

Today Patients Rising sent a letter to Dr. Heidi Overton at the White House Domestic Policy Council, asking the administration to use the tools it already has against a fast-growing black market: experimental weight-loss compounds that are still in clinical trials, sold online in vials labeled "research use only." [LINK: Read the full letter (PDF)]

What is being sold, and why it matters

Some of the most talked-about weight-loss therapies in development have not finished clinical trials, which means no one yet knows for certain whether they are safe, what dose is right, or who should take them. That has not stopped sellers. Overseas suppliers and domestic resellers are offering these compounds to the public, marketing them through social media, influencers, wellness clinics, and even corner stores, with a "research use only, not for human consumption" label on a product that is plainly being sold for people to inject.

The warning signs are real. The FDA has received at least two reports of deaths this year and more than a dozen reports of hospitalizations involving products sold under the name of one of these investigational therapies, and the nation's poison centers logged nearly twice as many exposures to that product in the three months ending in September as in the three months before. Those reports are unverified, and the cause of the harm is not yet known. But testing shows why no one should trust what is in these vials. Australia's drug regulator found a product sold under this name that held a different weight-loss drug and none of the compound on its label, and a recent news investigation found a vial bought at a corner store that contained no active drug at all, only a cosmetic filler and bacteria.

Why this is a patient issue

Patients Rising works to make health care safer, more affordable, and easier to reach, and on this issue those goals cannot be separated. People do not usually turn to a black market because they want to take a risk. They turn to it because an approved treatment is out of reach, whether because of cost, coverage, or a long wait, or because they have read about a promising therapy that is still years from approval. Wanting a better option is completely understandable. A vial with unknown contents, from a seller no one can hold accountable, is not that option. Every sale also undercuts the clinical trials that exist to tell patients whether a therapy is safe and whether it works.

What we asked for

Our letter makes three requests. First, enforce the laws already on the books. Selling an unapproved drug is illegal under federal law, and a "research use only" label does not change that when the product is clearly meant for people. The FDA has sent more than a dozen warning letters to sellers of this one compound since 2024, and the trade has kept growing, so we asked that sellers who keep going after a warning be referred to the Department of Justice. Second, secure the supply chain at the border, where much of this product enters the country from overseas manufacturers, through closer coordination among the FDA, Customs and Border Protection, and federal law enforcement. Third, hold accountable the people doing the selling, including the marketers and influencers who promote these products and the clinics and practitioners who supply them outside of a clinical trial, and work with online platforms to keep these products off their sites.

The other half of the answer

Enforcement matters, but it is only half the solution. Black markets grow where patients feel shut out of the legitimate one. The surest long-term protection is a system that gets safe, proven therapies to patients without needless delay or cost barriers, and we have asked to meet with the Domestic Policy Council to share what we hear from patients and to work on both halves of that problem.

If you have used one of these products

If you have injected a product sold as "research use only," talk with a doctor or pharmacist you trust, and tell them exactly what you took and where you got it. If you have had a side effect, you can report it to the FDA through MedWatch or by calling 1-800-FDA-1088. For an urgent question about a possible poisoning, call Poison Control at 1-800-222-1222. And if you turned to one of these products because the treatment you needed was out of reach, we want to hear from you. [ADD LINK: Share your story]

Sources:
CBS News reporting on FDA adverse event reports and poison center data (October 13, 2026); CBS News laboratory testing of products sold as an investigational weight-loss drug (October 21, 2026);
Public Citizen investigation of hospitalizations and FDA warning letters (June 2026); Australia's Therapeutic Goods Administration consumer safety advisory.